Supplementary Figure 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Overview of MET TKD mutations detected in pan-cancer cohorts. (A) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in the cohort #1 (711 MET TKD mutations among 664 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (B) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #1. (C) Distribution of MET TKD mutations across MET kinase domain for cohort #1. (D) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in cohort #2 (2,559 MET TKD mutations among 2,477 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (E) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #2. (F) Distribution of MET TKD mutation across MET kinase domain for cohort #2.